The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients

Robyn Scherber, Amylou Dueck, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria L. Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Ayalew Tefferi, Claire N. Harrison, Deepti Radia, Ruben A. Mesa

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients'responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.

Original languageEnglish (US)
Pages (from-to)401-408
Number of pages8
JournalBlood
Volume118
Issue number2
DOIs
StatePublished - Jul 14 2011

Fingerprint

Symptom Assessment
Neoplasms
Essential Thrombocythemia
Fatigue of materials
Polycythemia Vera
Primary Myelofibrosis
Language
Quality of Life
Sweden
Italy
Fatigue
Clinical Trials
Physicians
Equipment and Supplies

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) : International prospective validation and reliability trial in 402 patients. / Scherber, Robyn; Dueck, Amylou; Johansson, Peter; Barbui, Tiziano; Barosi, Giovanni; Vannucchi, Alessandro M.; Passamonti, Francesco; Andreasson, Bjorn; Ferarri, Maria L.; Rambaldi, Alessandro; Samuelsson, Jan; Birgegard, Gunnar; Tefferi, Ayalew; Harrison, Claire N.; Radia, Deepti; Mesa, Ruben A.

In: Blood, Vol. 118, No. 2, 14.07.2011, p. 401-408.

Research output: Contribution to journalArticle

Scherber, R, Dueck, A, Johansson, P, Barbui, T, Barosi, G, Vannucchi, AM, Passamonti, F, Andreasson, B, Ferarri, ML, Rambaldi, A, Samuelsson, J, Birgegard, G, Tefferi, A, Harrison, CN, Radia, D & Mesa, RA 2011, 'The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients', Blood, vol. 118, no. 2, pp. 401-408. https://doi.org/10.1182/blood-2011-01-328955
Scherber, Robyn ; Dueck, Amylou ; Johansson, Peter ; Barbui, Tiziano ; Barosi, Giovanni ; Vannucchi, Alessandro M. ; Passamonti, Francesco ; Andreasson, Bjorn ; Ferarri, Maria L. ; Rambaldi, Alessandro ; Samuelsson, Jan ; Birgegard, Gunnar ; Tefferi, Ayalew ; Harrison, Claire N. ; Radia, Deepti ; Mesa, Ruben A. / The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) : International prospective validation and reliability trial in 402 patients. In: Blood. 2011 ; Vol. 118, No. 2. pp. 401-408.
@article{050a864025fa424ba9e6dbdb837fcea9,
title = "The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients",
abstract = "Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25{\%}], Italian [46{\%}], and Swedish [28{\%}]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients'responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.",
author = "Robyn Scherber and Amylou Dueck and Peter Johansson and Tiziano Barbui and Giovanni Barosi and Vannucchi, {Alessandro M.} and Francesco Passamonti and Bjorn Andreasson and Ferarri, {Maria L.} and Alessandro Rambaldi and Jan Samuelsson and Gunnar Birgegard and Ayalew Tefferi and Harrison, {Claire N.} and Deepti Radia and Mesa, {Ruben A.}",
year = "2011",
month = "7",
day = "14",
doi = "10.1182/blood-2011-01-328955",
language = "English (US)",
volume = "118",
pages = "401--408",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)

T2 - International prospective validation and reliability trial in 402 patients

AU - Scherber, Robyn

AU - Dueck, Amylou

AU - Johansson, Peter

AU - Barbui, Tiziano

AU - Barosi, Giovanni

AU - Vannucchi, Alessandro M.

AU - Passamonti, Francesco

AU - Andreasson, Bjorn

AU - Ferarri, Maria L.

AU - Rambaldi, Alessandro

AU - Samuelsson, Jan

AU - Birgegard, Gunnar

AU - Tefferi, Ayalew

AU - Harrison, Claire N.

AU - Radia, Deepti

AU - Mesa, Ruben A.

PY - 2011/7/14

Y1 - 2011/7/14

N2 - Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients'responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.

AB - Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients'responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.

UR - http://www.scopus.com/inward/record.url?scp=79960437973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960437973&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-01-328955

DO - 10.1182/blood-2011-01-328955

M3 - Article

C2 - 21536863

AN - SCOPUS:79960437973

VL - 118

SP - 401

EP - 408

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -